News coverage about Edwards Lifesciences Corporation (NYSE:EW) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edwards Lifesciences Corporation earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.0113845603316 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- What Should You Know About Edwards Lifesciences Corporation’s (EW) Growth? (finance.yahoo.com)
- Edwards Lifesciences: Analyst Recommendations in November (finance.yahoo.com)
- Edwards Lifesciences: Expected to Report Robust Revenues in 2017 (finance.yahoo.com)
- Edwards Lifesciences: Small Rise in Net Profit Margins Expected (finance.yahoo.com)
- Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock (americanbankingnews.com)
Edwards Lifesciences Corporation (NYSE EW) traded down $0.01 during midday trading on Friday, reaching $107.09. The company’s stock had a trading volume of 1,071,667 shares, compared to its average volume of 1,910,742. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22,662.38, a PE ratio of 29.67, a P/E/G ratio of 1.92 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. During the same quarter last year, the business posted $0.68 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. equities analysts forecast that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.
EW has been the topic of a number of recent research reports. Deutsche Bank AG dropped their price objective on Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Morgan Stanley dropped their price objective on Edwards Lifesciences Corporation from $133.00 to $120.00 and set an “overweight” rating on the stock in a report on Thursday, October 26th. Barclays PLC dropped their price objective on Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 25th. SunTrust Banks, Inc. set a $124.00 price objective on Edwards Lifesciences Corporation and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Canaccord Genuity reissued a “buy” rating and set a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a report on Wednesday, October 25th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $125.17.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/19/edwards-lifesciences-corporation-ew-given-daily-media-sentiment-rating-of-0-20.html.
In other news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total value of $3,699,605.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the completion of the transaction, the director now owns 2,622 shares of the company’s stock, valued at approximately $273,081.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,540 shares of company stock valued at $17,130,243. Company insiders own 2.13% of the company’s stock.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.